生命科学资讯
生物技术与制药领域的最新动态
罗氏诊断业务在2025年微增2%，中国市场逆风冲击亚太区销售。
Roche diagnostics business nudges up 2% in '25 as China headwinds buffet Asia-Pacific sales
Roche GLP-1 produces “robust” weight loss in late-stage obesity trial - European Pharmaceutical Review
Roche drops $100M Kiniksa fibrosis drug from phase 2 pipeline as part of quarterly clearout - Fierce Biotech
罗氏公布GLP-1/GIP双重受体激动剂二期研究积极结果 | 医药行业高管
Roche Reports Positive Phase II Study Results for Dual GLP-1/GIP Receptor Agonist | PharmExec - Pharmaceutical Executive
罗氏在肥胖症领域落后，展示GLP-1注射剂新数据
Roche, trailing in obesity, showcases new data for GLP-1 shot
罗氏肥胖症突破后如何扩大生产规模 - 制造数字杂志
How Roche is Scaling Production After Obesity Breakthrough - Manufacturing Digital Magazine
罗氏旗下Carmot的GLP1/GIP药物实现22.5%减重效果，准备启动三期临床试验——Fierce Biotech
Roche sees GLP1/GIP drug from Carmot produce 22.5% weight loss, readies phase 3 trial - Fierce Biotech
罗氏宣布实验性肥胖药物二期临床试验结果积极 - wkzo.com
Roche announces positive phase II results for experimental obesity drug - wkzo.com
罗氏Gazyva获加拿大卫生部批准用于狼疮肾炎治疗 - marketscreener.com
Roche's Gazyva gets Health Canada approval for lupus nephritis - marketscreener.com
罗氏将北卡罗来纳州工厂投资增至20亿美元；伦茨勒首席执行官卸任
Roche boosts NC factory investment to $2B; Rentschler CEO steps down
Anthropic、罗氏与英伟达：本周医疗数字化热点聚焦
Anthropic, Roche & NVIDIA: This Week's Top Stories - Healthcare Digital
罗氏：让预防性医疗保健惠及所有人 - 医疗保健数字化
Roche: Making Preventative Healthcare Accessible to All - Healthcare Digital
《梯子与滑梯》——罗氏前肿瘤部门负责人转投Tubulis
Chutes & Ladders—Former Roche oncology head turns to Tubulis
前罗氏肿瘤部门负责人转投Tubulis——职业阶梯的升降记
Former Roche oncology head turns to Tubulis—Chutes & Ladders - fiercebiotech.com
罗氏重返中国生物技术公司美迪凯，再签ADC合作协议。
Roche returns to Chinese biotech MediLink for another ADC pact
罗氏重返中国生物技术公司美迪凯，达成另一项ADC合作协议
Roche returns to Chinese biotech MediLink for another ADC pact - Endpoints News
罗氏公开新型NLRP3炎症小体抑制剂
Roche divulges new NLRP3 inflammasome inhibitors
罗氏重返与美迪凯合作，承诺为另一ADC支付近5.7亿美元短期款项。
Roche returns to MediLink with promise of $570M near-term payments for another ADC
罗氏重返美迪联，以5.7亿美元近期付款获取ADC技术——Fierce Biotech报道
Roche returns to MediLink with $570M near-term payments for ADC - Fierce Biotech